I wouldn’t call it ‘bashing’ to question the specifics of the deals, lack of promised revenue from prior deals, lawsuit galore, time lines not met, lack of major updates, etc. That is holding management to task, not bashing. It would only be considered bashing if management had completed all of the above, and yet still the negative posts.
(1)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Disclaimer: Of course, all of this is my opinion and you should not make any investment decisions based on my opinion. I have not received any non-public information.